287 related articles for article (PubMed ID: 33221464)
21. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
Zachariae C; Gordon K; Kimball AB; Lebwohl M; Blauvelt A; Leonardi C; Braun D; McKean-Matthews M; Burge R; Cameron G
J Am Acad Dermatol; 2018 Aug; 79(2):294-301.e6. PubMed ID: 29653208
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
Lebwohl MG; Blauvelt A; Menter A; Papp KA; Guenthner S; Pillai R; Israel RJ; Jacobson A
Am J Clin Dermatol; 2019 Dec; 20(6):863-871. PubMed ID: 31493163
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
Lo Y; Tsai TF
Br J Dermatol; 2019 Nov; 181(5):1106-1107. PubMed ID: 31145806
[No Abstract] [Full Text] [Related]
25. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
[TBL] [Abstract][Full Text] [Related]
26. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.
Giunta A; Ventura A; Chimenti MS; Bianchi L; Esposito M
Drug Des Devel Ther; 2017; 11():1643-1651. PubMed ID: 28652702
[TBL] [Abstract][Full Text] [Related]
27. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.
Gaspari AA; Tyring S
Dermatol Ther; 2015; 28(4):179-93. PubMed ID: 26201310
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis.
Loft N; Halling AS; Egeberg A; Skov L
J Am Acad Dermatol; 2021 Jan; 84(1):130-138. PubMed ID: 32730851
[TBL] [Abstract][Full Text] [Related]
29. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience.
Ohata C; Ohyama B; Katayama E; Nakama T
J Dermatol; 2020 Apr; 47(4):405-408. PubMed ID: 31994229
[TBL] [Abstract][Full Text] [Related]
30. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
31. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.
Campa M; Menter A
Expert Opin Investig Drugs; 2016 Nov; 25(11):1337-1344. PubMed ID: 27687859
[TBL] [Abstract][Full Text] [Related]
32. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
33. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
34. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
[TBL] [Abstract][Full Text] [Related]
35. Safety of secukinumab in psoriasis patients with latent tuberculosis infection.
Machado Á; Abreu M; Torres T
Eur J Dermatol; 2020 Dec; 30(6):740-741. PubMed ID: 33237033
[No Abstract] [Full Text] [Related]
36. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
Danset M; Hacard F; Jaulent C; Nosbaum A; Berard F; Nicolas JF; Goujon C
Eur J Dermatol; 2020 Dec; 30(6):741-743. PubMed ID: 33337328
[No Abstract] [Full Text] [Related]
37. Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Thomas SE; Seyger MMB; Mangnus JE; Otero ME; Gostynski AH; Njoo MD; Ossenkoppele PM; Haeck IM; Hendricksen-Roelofzen JHJ; Körver JEM; Dodemont SRP; Tupker RA; Berends MAM; Weppner-Parren LMJT; Keijsers RRMC; Oostveen AM; Peters B; Mommers R; van Doorn MBA; Tjioe M; Veldkamp WR; Kuijpers ALA; Kleinpenning MM; de Jong EMGJ; van den Reek JMPA
Am J Clin Dermatol; 2024 Jul; 25(4):685-688. PubMed ID: 38802618
[No Abstract] [Full Text] [Related]
38. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.
Georgakopoulos JR; Phung M; Ighani A; Yeung J
J Am Acad Dermatol; 2018 Jul; 79(1):155-157. PubMed ID: 29307635
[No Abstract] [Full Text] [Related]
39. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
[TBL] [Abstract][Full Text] [Related]
40. Concurrent Atopic Dermatitis and Psoriasis Successfully Treated With Brodalumab.
Gambardella A; Licata G; De Rosa A; Pagliuca F; Calabrese G; Alfano R; Argenziano G
Dermatitis; 2021 Oct; 32(1S):e86-e88. PubMed ID: 33208631
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
